Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen

Ag activation of the BCR may play a role in the pathogenesis of human follicular lymphoma (FL) and other B cell malignancies. However, the nature of the Ag(s) recognized by tumor BCRs has not been well studied. In this study, we used unbiased approaches to demonstrate that 42 (19.35%) of 217 tested FL Igs recognized vimentin as a shared autoantigen. The epitope was localized to the N-terminal region of vimentin for all vimentin-reactive tumor Igs. We confirmed specific binding to vimentin by using recombinant vimentin and by performing competitive inhibition studies. Furthermore, using indirect immunofluorescence staining, we showed that the vimentin-reactive tumor Igs colocalized with an anti-vimentin mAb in HEp-2 cells. The reactivity to N-terminal vimentin of IgG FL Igs was significantly higher than that of IgM FL Igs (30.4 versus 10%; p = 0.0022). However, vimentin-reactive FL Igs did not share CDR3 motifs and were not homologous. Vimentin was expressed in the T cell–rich regions of FL, suggesting that vimentin is available for binding with tumor BCRs within the tumor microenvironment. Vimentin was also frequently recognized by mantle cell lymphoma and multiple myeloma Igs. Our results demonstrate that vimentin is a shared autoantigen recognized by nonstereotyped FL BCRs and by the Igs of mantle cell lymphoma and multiple myeloma and suggest that vimentin may play a role in the pathogenesis of multiple B cell malignancies. These findings may lead to a better understanding of the biology and natural history of FL and other B cell malignancies.

[1]  Ash A. Alizadeh,et al.  Self-antigen recognition by follicular lymphoma B-cell receptors. , 2012, Blood.

[2]  G. Hughes,et al.  Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. , 2010, Blood.

[3]  Ash A. Alizadeh,et al.  B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression , 2010, Proceedings of the National Academy of Sciences.

[4]  J. Winter,et al.  Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Xiao-Jie Yan,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. , 2007 .

[6]  N. Rawal,et al.  Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor , 2008, The Journal of Immunology.

[7]  L. Dölken,et al.  Age-dependent prevalence and frequency of circulating t(14;18)-positive cells in the peripheral blood of healthy individuals. , 2008, Journal of the National Cancer Institute. Monographs.

[8]  R. Rosenquist,et al.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.

[9]  T. Podor,et al.  Vimentin autoantibodies induce platelet activation and formation of platelet‐leukocyte conjugates via platelet‐activating factor , 2008, Journal of leukocyte biology.

[10]  N. Marceau,et al.  Dual roles of intermediate filaments in apoptosis. , 2007, Experimental cell research.

[11]  M. Nussenzweig,et al.  Autoreactivity in human IgG+ memory B cells. , 2007, Immunity.

[12]  Jonathan M Irish,et al.  Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. , 2006, Blood.

[13]  B. Nadel,et al.  Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis , 2006, The Journal of experimental medicine.

[14]  J. Leonard,et al.  Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Stevens,et al.  Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. , 2006, The Journal of infectious diseases.

[16]  D. Girard,et al.  Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis , 2006, Journal of leukocyte biology.

[17]  M. Nussenzweig,et al.  A checkpoint for autoreactivity in human IgM+ memory B cell development , 2006, The Journal of experimental medicine.

[18]  P. Ferrara,et al.  SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sézary Cells1 , 2006, The Journal of Immunology.

[19]  Craig W. Reynolds,et al.  Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma , 2005, Nature Medicine.

[20]  Fran Lewitter,et al.  Intragenic tandem repeats generate functional variability , 2005, Nature Genetics.

[21]  B. Barlogie,et al.  Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma , 2005, Bone Marrow Transplantation.

[22]  R. Schelonka,et al.  Development of the Expressed Ig CDR-H3 Repertoire Is Marked by Focusing of Constraints in Length, Amino Acid Use, and Charge That Are First Established in Early B Cell Progenitors1 , 2005, The Journal of Immunology.

[23]  E. Meffre,et al.  Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. , 2005, The Journal of clinical investigation.

[24]  D. de Jong,et al.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity , 2005, The Journal of experimental medicine.

[25]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[26]  M. C. Popescu,et al.  Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.

[27]  W. Vanvenrooij,et al.  Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[28]  D. Markovitz,et al.  The Endothelial Cell-Specific Antibody PAL-E Identifies a Secreted Form of Vimentin in the Blood Vasculature , 2004, Molecular and Cellular Biology.

[29]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor VJ and VDJrearrangement analysis , 2004, Nucleic Acids Res..

[30]  Anna Tramontano,et al.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. , 2004, The Journal of clinical investigation.

[31]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[32]  J. Engler,et al.  Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. , 2003, Journal of molecular biology.

[33]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[34]  T. Hamblin,et al.  Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. , 2002, Blood.

[35]  R. Bende,et al.  Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load. , 2000, Blood.

[36]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[37]  D. Jong,et al.  Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. , 1995, Blood.

[38]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[39]  D. Bahler,et al.  Clonal evolution of a follicular lymphoma: evidence for antigen selection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Miller,et al.  Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. , 1991, Blood.

[41]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[42]  P. Youinou,et al.  Relation of antivimentin antibodies to anticardiolipin antibodies in systemic lupus erythematosus. , 1988, Annals of the rheumatic diseases.

[43]  W. Carroll,et al.  Mouse x human heterohybridomas as fusion partners with human B cell tumors. , 1986, Journal of immunological methods.

[44]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[45]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[46]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[47]  R. Bende,et al.  Molecular pathways in follicular lymphoma , 2007, Leukemia.

[48]  D. Markovitz,et al.  Vimentin is secreted by activated macrophages , 2003, Nature Cell Biology.

[49]  D. Eisenberg.  Three-dimensional structure of membrane and surface proteins. , 1984, Annual review of biochemistry.